UBASH3B and neoplasm: Integrated spatial transcriptomics, single-cell RNA sequencing and TCR profiling revealed the UBASH3B-driven axis to be specially localized to tumor-associated macrophages (TAMs), tumor cells, and T-cells, within the TME, and contributed to the formation of a lipid-rich immunosuppressive niche that impaired T-cell cytotoxic reactivation and correlated with poor response to anti-PD1 therapy (neoadjuvant nivolumab therapy) [70].